Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05275205 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
A Phase 2 study of Neovascular Age-related Macular Degeneration, sponsored by Unity Biotechnology.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 14
- Study locations
NCT05275205 is a Phase 2 study of Neovascular Age-related Macular Degeneration that has completed, run by Unity Biotechnology. The registered enrollment target is 51 participants, below the 407-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (87% lower). The trial reports 14 study locations across 9 states.
The verdict
NCT05275205, a Phase 2 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Unity Biotechnology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 14
- Study locations
Study Summary
This study is intended to assess safety, tolerability and biological activity of a repeat IVT injection of UBX1325 in patients with wet AMD.
Conditions Studied
Interventions
- DRUG UBX1325 injection 50 μL
- DRUG EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Study Locations (14)
Texas
- Retina Research Institution of Texas - Abilene
- Valley Retina Institute - McAllen
- Austin Retina Associates - Round Rock
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
- Salehi Retina Institute - Huntington Beach
Florida
- Rand Eye Institute - Deerfield Beach
- Retina Vitreous Associates of Florida - St. Petersburg
Illinois
- University Retina and Macula Associates - Lemont
- Illinois Eye Center - Peoria
Colorado
- Advanced Vision Research Institute - Longmont
Indiana
- Midwest Eye - Carmel
Minnesota
- Mayo Clinic-Rochester - Rochester
Nevada
- Sierra Eye Associates - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2022-03-02 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05275205
The ClinicalTrials.gov registry entry for NCT05275205 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 407-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (87% lower). The listed sponsor is Unity Biotechnology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which UBX1325 injection 50 μL is the first listed.
NCT05275205 reports 14 study locations spanning 9 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05275205 about?
NCT05275205 is a clinical study titled "Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)". This study is intended to assess safety, tolerability and biological activity of a repeat IVT injection of UBX1325 in patients with wet AMD.
What is the current status of trial NCT05275205?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2022-03-02. Estimated completion is 2023-07-25.
What conditions does trial NCT05275205 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT05275205?
The interventions under investigation include: UBX1325 injection 50 μL (DRUG), EYLEA® (aflibercept) Injection 2 mg (0.05mL) (DRUG).
Who is sponsoring clinical trial NCT05275205?
This trial is sponsored by Unity Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05275205 being conducted?
This trial has 14 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
COMPLETED · Phase 2
-
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
COMPLETED · Phase 2
-
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.